Literature DB >> 19541527

RA treatment study group: improvement in RA management.

Michael Ward1, Matthew H Liang, Thomas Burns, Gurkirpal Singh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19541527      PMCID： PMC2761244          DOI： 10.1016/j.jbspin.2009.05.003

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN： 1297-319X            Impact factor:   4.929


× No keyword cloud information.
  6 in total

1.  Disease modifying treatment and elective surgery in rheumatoid arthritis: the need for more data.

Authors:  A Jain; R Maini; J Nanchahal
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

2.  Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery.

Authors:  S C Talwalkar; D M Grennan; J Gray; P Johnson; M J Hayton
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

3.  Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR).

Authors:  Thao Pham; Pascal Claudepierre; Xavier Deprez; Bruno Fautrel; Philippe Goupille; Pascal Hilliquin; Charles Masson; Jacques Morel; Xavier Puéchal; Alain Saraux; Thierry Schaeverbeke; Xavier Mariette; Jean Sibilia
Journal:  Joint Bone Spine       Date:  2005-06       Impact factor: 4.929

4.  Elective orthopedic surgery and perioperative DMARD management: many questions, fewer answers, and some opinions...

Authors:  Tim Bongartz
Journal:  J Rheumatol       Date:  2007-04       Impact factor: 4.666

5.  Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis.

Authors:  Inmaculada del Rincón; Gregory L Freeman; Roy W Haas; Daniel H O'Leary; Agustín Escalante
Journal:  Arthritis Rheum       Date:  2005-11

6.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  N Engl J Med       Date:  2008-11-09       Impact factor: 91.245
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.